Two views: country-level market data, and archetype intelligence. Data compiled June 2026.
Population vs. HRT adoption
Bubble size = women aged 45–60 (millions). X = avg menopause age. Y = HRT adoption %. Hover for detail.
What women spend on, by income group
Category mix shifts with income. Lower-income women spend almost entirely on OTC supplements and traditional medicine; higher-income women access HRT, telehealth, and specialised products.
↗ US reference ~$13B/year (Grand View Research / industry estimates, no public methodology). ~ Category splits are directional estimates derived from income-group proxies, not measured per-category spend data.
Country data
Click headers to sort. Hover a row for notes. HRT shown as absolute (millions) + percentage. † = estimated.
| Country | Region | Income | Meno age | Peri starts | Women 45–60 | On HRT (out of total) | $/woman/yr | Market | Data confidence |
|---|
✓ World Bank FY26 income thresholds. ✓ NIH / NAMS for US/clinical data. ↗ Grand View Research for market sizing (commercial, no public methodology). ~ Per-woman spend = regional market ÷ estimated women 45–60; directional only. Most non-US/UK rows are modeled, see methodology below.
High US and UK only. US: NIH NHANES-derived HRT use (6.1% systemic), Mayo Clinic care-seeking data, NHS prescribing records for UK (11M items 2022–23). These are empirical measurements.
Medium UK (Rx data available). Limited to countries with published national prescription databases or academic survey data.
Estimate† All other countries. HRT adoption %, silent sufferer %, and per-woman spend are modeled from: (a) HRT adoption proxies from regional pharmaceutical reports, (b) healthcare access indices (World Bank), (c) academic literature on stigma and help-seeking. Treat as order-of-magnitude, not precise.
Calculated as menopause age − 6 for all countries. This is a rough approximation based on the NAMS guideline that perimenopause typically begins 4–8 years before menopause. No per-country empirical data is used for this field.
The three archetypes are an analytical construct created for this dashboard, not a validated clinical taxonomy. A1 is estimated as popM × silentPct/100. A3 is estimated as women on HRT (hrtAbsM). A2 is the remainder. Because silentPct for most countries is itself an estimate, the archetype splits carry compounded uncertainty outside US/UK.
Key behavioral statistics (e.g. "56% wished they knew earlier," "31% didn't treat sooner," "71% felt unprepared") come from the Bonafide State of Menopause 2025 and Pharmavite 5th Annual Study 2025. Both companies sell menopause supplements. Their research is methodologically plausible (n=2,000+) but should be read as industry-sponsored advocacy research, not independent evidence. Carrot/OLLY survey data carries the same caveat.
"PMC 2023" (UK silent sufferer rate), PubMed Central is a repository, not a source. Specific paper not identified. · "UVA Study on early symptom onset", no title, year, or journal cited. · "TandFonline WTP vasomotor study 2023", Taylor & Francis is a publisher; specific journal/authors unknown. · "Mayo Clinic (2025), 80% don't seek care", likely a Mayo health information page citing other research, not original Mayo research.
No data for: Saudi Arabia, UAE, Turkey, Egypt, Philippines, Vietnam, Thailand, Eastern Europe, or most of Latin America and sub-Saharan Africa. These omissions represent hundreds of millions of women in the 45–60 age band.
Country deep-dive
Pick any country in your filter to see its full profile: archetype population split, silent sufferer rate, misdiagnosis pattern, what converts her, key barrier, and hidden spend.
The global care funnel
Of ~1.38 billion women in peri/menopause globally, the overwhelming majority never receive appropriate care.
? "Mayo Clinic (2025), 80% don't seek care", likely a Mayo health information page citing other research, not original Mayo research. Needs primary source verification. ✓ Misdiagnosis rate ~40% (Contemporary OB/GYN 2024, n=1,000+, verify study exists as described). ✓ US HRT use 6.1% systemic (NIH/NHANES). Global funnel totals (~1.38B, 80%, 12%) derived from country-level estimates, not independently cited.
The three archetypes
Select an archetype above, the relevant card glows and all sections below dim or highlight accordingly.
Silent sufferers, by country A1 + A2
% who never seek formal care. Updates live with your region + income filter, ordered by severity.
? US: Mayo Clinic 2025 (health info page, primary source unverified). ? UK: "PMC 2023", no specific paper identified; PubMed Central is a repository. ~ All other countries: modeled from HRT adoption rates, World Bank healthcare access indices, and stigma literature, not direct survey data. Treat non-US/UK figures as order-of-magnitude estimates only.
The misdiagnosis trap A1 + A2
~40% of perimenopausal women report misdiagnosis. What they're told instead (Contemporary OB/GYN 2024, n=1,000+).
✓ Contemporary OB/GYN 2024, n=1,000+ (verify this specific study). 39% of women diagnosed with depression believed they had the wrong diagnosis. ✓ Avg ob-gyn gets <2 hours menopause training in 4 years (NAMS training audit, widely cited in peer-reviewed literature).
What converts her to action A1 → A2 lever
What finally moves archetype 1 → archetype 2. This is your acquisition lever.
⚑ Bonafide State of Menopause 2025 (n=2,000+, Bonafide is a supplement brand; results likely overstate activation potential). ✓ Catalyst Global Survey 2024 (nonprofit, more independent). ? Mayo Clinic 2025 (health info page, primary source unverified).
What they say they wish existed, in their own words
From Bonafide State of Menopause 2025 (n=2,000+), Pharmavite 5th Annual Study 2025, Catalyst Global Survey 2024, r/menopause and r/perimenopause. Use archetype filter to highlight one column.
Time in each stage, the acquisition window
How long women spend in each archetype shapes urgency, messaging, and product design. The "unaware" window is long and currently owned by no one.
✓ NAMS clinical guidelines (peer-reviewed). ⚑ Pharmavite 2025 (supplement brand, industry-funded). ? Mayo Clinic 2025 (health info page). ? "UVA Study on early symptom onset", no title, authors, year, or journal cited; needs specific verification.
Discovery channels, how each archetype finds her way in
Where each archetype discovers, researches, and accesses solutions. This is the go-to-market layer. Use the archetype filter above to focus on one column.
⚑ Bonafide 2025 (supplement brand). ⚑ Carrot/OLLY survey 2025 (OLLY is a supplement brand; Carrot sells employer benefits in this space). ~ TikTok 1B+ #menopause views (platform self-reported; not independently verified). ↗ Nutraingredients 2025 (trade publication, supplement industry). ↗ Grand View Research (commercial, no public methodology).
Willingness to pay vs. actual spend A2 + A3
What she IS currently paying (often for the wrong things) vs. what she would pay for a solution that actually works. The gap is the business opportunity.
✓ GoodRx Cost of Menopause Survey 2025 (n=1,500, YouGov methodology, GoodRx has commercial interest but YouGov polling is credible). ? "TandFonline WTP vasomotor study 2023", Taylor & Francis is a publisher, not a study; specific journal, authors, and paper title not cited. WTP figures ($35–46/mo) are plausible but need primary source. ~ Midi Health + Joi pricing = observed market rates (verifiable). Medication cost +58% over decade (GoodRx, 2025).
The employer / B2B opportunity
Menopause costs employers more than they realise, and most haven't started solving it. Parallel go-to-market to DTC, and currently the most fundable framing in women's health.
✓ SHRM 2025 (Society for Human Resource Management, credible HR industry org). ⚑ Carrot Menopause in the Workplace 2025 (Carrot sells employer benefits, industry-funded). ✓ Catalyst 2024 (nonprofit workplace inclusion, more independent). ✓ AARP 2025 $26B US productivity figure (verify specific report). ~ $150B global figure (IBI/Carrot, very large extrapolation; Carrot is a vendor). ✓ UK CIPD + Wellbeing of Women (credible). Progyny April 2026 = company announcement, not independent research. FTSE 100: Diversity Q / People Management 2024 (CIPD publication, credible for UK).